Background: This study investigated the effects of Korean red ginseng (KRG) supplementation on metabolic parameters, inflammatory markers, and arterial stiffness in subjects with metabolic syndrome.
INTRODUCTION
Metabolic syndrome represents a cluster of cardiometabolic risk factors, including central obesity, elevated blood pressure, impaired glucose metabolism, and atherogenic dyslipidemia.
The prevalence of metabolic syndrome is currently reaching epidemic proportions throughout the world. Subjects with metabolic syndrome are more susceptible to type 2 diabetes, 1) cardiovascular disease (CVD), 1) and some cancers, 2) which are major leading causes of death, especially in developed countries.
Panax ginseng has been used to promote general health and treat illness in traditional oriental medicine. Particularly, Korean red ginseng (KRG) has been reported to have various beneficial effects on vascular health, energy metabolism, pain-relief, and cancer prevention. 3) Many animal studies have shown that KRG has potential benefits on cardiovascular disease and several metabolic parameters, [4] [5] [6] [7] [8] but human studies have not provided
consistent evidence yet. [9] [10] [11] [12] [13] [14] Moreover, although most human studies have been conducted in patients with individual diseases, such as hypertension, diabetes, and hyperlipidemia, little is known about the effects of KRG on cardiovascular risks in subjects with metabolic syndrome.
The aim of this double-blind, placebo-controlled, randomized study was to investigate the effects of KRG on cardiovascular risks in subjects with metabolic syndrome, including blood pressure, fasting plasma glucose, insulin sensitivity, lipid profile, oxidized low density lipoprotein (LDL) level, and arterial stiffness. 
METHODS

Study Subjects
Measurements
We collected anthropometric measurements, blood for Arterial stiffness was measured via baPWV using a volumeplethysmographic apparatus (PWV/ABI; Colin Co., Komaki, Japan). The coefficients of variation were 8.4% for interobserver reproducibility and 10.0% for intraobserver reproducibility.
Sample Size Estimation
The intended sample of 60 recruited subjects provided a power of approximately 80%, assuming a significance level 
Statistical Analysis
Data are presented as mean ± SD. The primary outcome (blood pressure and arterial stiffness) and the secondary outcome (metabolic and inflammatory markers) were used to compare the KRG group to the placebo group. The Wilcoxon signedrank test was used to calculate the significances of the differences from baseline in each group. The effects of treatment relative to the control levels were analyzed by comparing the changes from baseline between the two treatment arms using Wilcoxon ranksum test. All analyses were conducted using SAS ver. 9.1 (SAS Inc., Cary, NC, USA). All statistical tests were two-sided, and a P < 0.05 was considered significant. 
RESULTS
The study criteria were met by 60 subjects who were randomized for participation. We defined good compliance as taking more than 80% of the pills given to the participants. Of these, 12 subjects withdrew (11 due to noncompliance and 1 due to time conflicts) and 48 subjects completed the study (KRG group, n = 23; placebo group, n = 25) (Figure 1) . According to the self-reported questionnaire, one subject reported gastrointestinal disturbance after placebo administration, whereas there were no reported adverse reactions to KRG administration.
Baseline characteristics of all subjects are presented in Table   1 . The following parameters were similar in both the KRG and placebo group: age, waist circumference, systolic blood pressure, diastolic blood pressure, fasting plasma glucose, total cholesterol, HDL-cholesterol, triglyceride, insulin, oxidized LDL, CRP, leukocyte count, and baPWV. Table 2 summarizes the interand intra-group differences in metabolic parameters, arterial stiffness, and inflammatory markers. Mean waist circumference and systolic blood pressure decreased significantly in the KRG group (P = 0.015 and P = 0.038, respectively) and mean HDLcholesterol increased in the KRG group (P = 0.019). Mean systolic blood pressure and diastolic blood pressure decreased in the placebo group (P < 0.001 and P < 0.001, respectively).
However, the extent of change in waist circumference, blood pressure, and HDL-cholesterol between the KRG and placebo groups was not significantly different. Oral administration of KRG did not significantly affect blood pressure; inflammatory markers, including oxidized LDL, CRP, and leukocyte count; or baPWV. 
DISCUSSION
In this double-blind, randomized, and placebo-controlled study, there was no significant improvement in metabolic parameters, oxidative or inflammatory markers, or baPWV after oral administration of KRG compared to the placebo group.
Central obesity is a core characteristic of metabolic syndrome.
Increased visceral adipose tissues are accompanied by chronic low grade inflammation and insulin resistance, which explains various features of metabolic syndrome. Adipose tissue is now accepted as an endocrine organ that secretes a variety of adipokines and cytokines. Thus, metabolic syndrome is implicated by an increased production of proinflammatory cytokines, such as interleukin-6 and tumor necrosis factor-α. 18, 19) These cytokines play a key role in regulating the vessel wall tone by affecting the release of nitric oxide and endothelin-1 in the subendothelial space. 20, 21) This cascade may cause endothelial dysfunction and alter arterial elastic properties, leading to increased blood pressure and structural stiffness. KRG has several constituents with curable properties, of which ginsenosides have been noticed to be a major pharmacologic component. In animal studies and an in vitro study using human umbilical vein endothelial cell, [22] [23] [24] ginsenosides relax blood vessels and improve blood flow through nitric oxide release by activating endothelial nitric oxide synthase.
Human clinical trials have demonstrated that KRG has favorable effects on blood pressure, and the study included a range of subjects, from those in good health to patients with congestive heart failure, but the majority of patients did not demonstrate a significant change in response to KRG administration. 25) Han et al. 10) reported that red ginseng significantly decreased systolic blood pressure in essential hypertension patients without antihypertensive medication. Some studies have reported that ginseng slightly increased blood pressure, 9, 26) but the study was conducted in healthy subjects. Therefore, there was a possibility that KRG's effects vary according to baseline blood pressure.
We excluded subjects who were currently taking drugs that could modify metabolic and vascular function parameters, and patients in need of medical treatment. This may have resulted in a study population with relatively early metabolic syndrome that KRG has also been reported to improve insulin resistance and have anti-hyperlipidemic effects. 7, 11, 27) Furthermore, some studies have indicated that KRG might reduce weight gain. 28, 29) Although the reason for favorable energy metabolism of KRG is unclear, it may be explained by activation of adenosine monophosphateactivated protein kinase 29) and reductions in food intake or appetite. 30) However, firm evidence is still lacking in clinical trials.
25)
The lack of beneficial effects for KRG in this study has several possible explanations. First, we could not fully control participants' lifestyle such as exercise and diet. Although all participants were instructed to exercise on a regular basis and mildly reduce their calorie intake, each individual's compliance may have been different. Second, the relationship between KRG dosage and its effect on CVD risks was not evaluated. Further research is warranted to clarify the influence of a dose-effect relationship to determine the optimum dosage in subjects with metabolic syndrome. Third, the ginsenoside Rg3 has been known to improve insulin sensitivity, 31) but the 0.22% of Rg3 used in this study may be too low to be expected to have any beneficial effects on metabolic parameters. Lastly, gender differences were not considered. Further investigation is warranted to better understand gender differences in the cardiovascular effects of KRG in subjects with metabolic syndrome.
In conclusion, we found no evidence that KRG had an effect on blood pressure, lipid profile, oxidized LDL, fasting blood glucose, or arterial stiffness in subjects with metabolic syndrome.
These findings warrant further longer-term prospective clinical investigations with a larger population.
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